Avacta Group plc (GB:AVCT) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Avacta Group plc is set to present new preclinical data on their revolutionary pre|CISION™ cancer treatment platforms at the 2024 EORTC-NCI-AACR Symposium. The company’s advancements include AVA6103, a potent peptide drug conjugate designed for tumor-specific delivery, and a new class of Affirmer® Drug Conjugates aiming for higher specificity and reduced systemic exposure. These innovations highlight Avacta’s commitment to developing highly targeted cancer therapies with the potential to improve patient outcomes.
For further insights into GB:AVCT stock, check out TipRanks’ Stock Analysis page.